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always resistant to all b-lactams without any
exception.
The reason why NaCl increases resistance to
vancomycin, as described previously [9], is not
known, nor is the reason for the decrease in the
MIC of teicoplanin, which to our knowledge has
never been reported previously. Antagonism
between b-lactams and vancomycin is very clear
in the presence of NaCl 4%w ⁄ v (Fig. 1b), and this
is particularly true for strain Mu3. For some other
strains, the persistance of a few colonies within
the b-lactam inhibition zone indicates that at least
part of the population is not inhibited by high
concentrations of b-lactams in the presence of
vancomycin. Moreover, because of the short half-
life of most b-lactams, it is anticipated that only
low b-lactam levels are present to interact with
glycopeptides for quite a long period. However,
at high vancomycin concentrations, and for a very
limited MIC range (0.5–1 mg ⁄L), the interaction
between vancomycin and b-lactams can be con-
sidered as synergistic.
In contrast to vancomycin, the interaction
between teicoplanin and b-lactams is more often
synergistic, as has been demonstrated previ-
ously for teicoplanin-resistant isolates of Staphy-
lococcus epidermidis [11]; in the presence of NaCl
there is enhanced synergy, depending on the
precise concentration of the b-lactam (data not
shown).
The precise clinical significance and reasons for
these results are unknown, but it can be conclu-
ded that vancomycin should not be used in
association with b-lactams for the treatment of
GISA infections.
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A B S T R A C T
Sera from 150 consecutive patients with estab-
lished asthma and 150 matched controls were
examined for Chlamydia pneumoniae IgG and IgA
with commercially available enzyme immunoas-
says (EIAs) detecting immune response solely to
surface proteins of elementary bodies. The assays
were also modified to measure combined immune
response to surface proteins and family-specific
lipopolysaccharide antigen. Mycoplasma pneumo-
niae IgG and IgA were measured with new
commercial EIAs utilising P1-enriched protein
fraction as an antigen. No statistically significant
differences between the patient groups in terms of
prevalence or levels of antibodies to either organ-
ism were found with these methods.
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A possible association between Chlamydia pneumo-
niae infection and adult-onset asthma was first
reported by Hahn et al. [1]. Some subsequent
investigations confirmed the relationship between
increased C. pneumoniae antibody titres and bron-
chial hyper-responsiveness and exacerbation of
asthma in adults [2–5] or children [6], but results of
other studies failed to confirm this association [7–
9]. The possible association between Mycoplasma
pneumoniae and asthma is also rather controversial
[9–11]. Most such seroepidemiological studies
have been performed using the microimmunoflu-
orescence (MIF) method, but there has been a
growing interest in other methodological approa-
ches. Thus, Schumacher et al. [12] showed that the
outcome and clinical conclusion regarding the
association between C. pneumoniae and coronary
heart disease was dependent on the method
chosen. The present study aimed to investigate
whether detection of combined C. pneumoniae
antibody to both lipopolysaccharide (LPS) and
surface proteins, compared to surface proteins
only, would influence the results obtained. In
addition, the possible association between M.
pneumoniae and asthma was examined using new
specific enzyme immunoassays (EIAs) [13].
During the period 1998–2000, 150 consecutive
patients (60 men and 90 women; mean age
37.3 years) from Smolensk Clinical Hospital (Rus-
sia) with established asthma were included in the
study on the basis of the following criteria: an
increase of ‡ 15% in forced expiratory volume
(FEV1) after inhalation of a bronchodilator
(b2-agonist with a short action); and ⁄ or an increase
of ‡ 20% in peak expiratory flow (PEF) after
inhalation of a bronchodilator (b2-agonist with a
short action); and ⁄ or variation in FEV1 (PEF) of
‡ 20% within a day on more than one occasion,
with no radiological evidence of other pulmonary
diseases during the previous 2 years. The adult
onset of asthma was determined by questionnaire.
Healthy volunteers (62 men and 88 women;
mean age 34.5 years) with no clinical symptoms of
asthma were frequency matched to asthma pa-
tients by age and sex, and included in a control
group for comparison. The exclusion criteria for
both groups were: a previous history of acute and
chronic upper and lower respiratory tract diseases
other than asthma; age > 55 years; serious under-
lying diseases (neoplasms, pulmonary diseases,
chronic coronary heart disease); immunotherapy
within the year before enrolment in the study; and
antibiotic therapy during the current exacerbation
of asthma. Signed informed consent was obtained
from all subjects before enrolment. The research
protocols were approved by the Ethical Commit-
tee of the Smolensk State Medical Academy.
After collection, sera were stored at )80 C and
sent in dry ice to the ThermoLabsystems (Hel-
sinki, Finland) laboratory for analysis. All assays
were performed blind by the same technician
with the same batch of reagents. C. pneumoniae
IgG and IgA antibodies were measured according
to the instructions for the Chlamydia pneumoniae
IgG and IgA EIA Kits (ThermoLabsystems). These
assays measure antibodies to the surface protein
antigens only. For the present study, the compo-
nents of the kit were also optimised to allow the
measurement of combined anti-protein and anti-
LPS antibodies. The cut-offs for positivity were
those recommended in the current kit instruc-
tions, namely > 45 EIUs (enzyme-immune units)
for IgG and > 12 EIUs for IgA, irrespective of the
conventional or modified assays being used.
M. pneumoniae antibodies were measured
according to the instructions for the ThermoLab-
systems Mycoplasma pneumoniae IgG and IgA EIA
Kits. In these EIAs, antibody responses are meas-
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ured to the enriched P1-protein [13], which is the
major immunogen. In all assays the results were
calculated in EIUs as the net absorbance of the
sample divided by the net absorbance of the
respective calibrator multiplied by 100.
Before analysis, the numerical values of EIUs
were rounded to integers. The qualitative compar-
ison was performed by the Fisher exact test (two-
tail) and the continuous variables were analysed by
Student’s t-test. For qualitative analysis, adjust-
ment for confounding factors was performed using
a logistic regression model that included the
following variables: group (asthma or control),
sex and smoking history; quantitative analysis
adjustment was performed using the ANOVA model,
including the group (control or asthma), age, body-
mass index, sex and smoking history.
Table 1 shows the qualitative analysis of serop-
ositivity using the Fisher two-tail exact test for the
asthma vs. control groups for all analytical param-
eters studied. There was no significant difference
between the patient groups for any parameter
investigated. Table 2 shows the quantitative analy-
sis of specific antibody levels using the ANOVA
model. As with the qualitative analysis, no signifi-
cant differences were detected between the patient
groups. Thus, no association was detected between
C. pneumoniae and M. pneumoniae infections and
asthma with the methods used. These methods
have been evaluated extensively elsewhere [12,14–
19] and appear to be at least as reliable as any other
in-house or commercial MIF method.
In contrast to other investigators who used
different criteria for chronic infections, the cut-
offs for positivity were those recommended in the
kits and defined in previous clinical studies
[13,15–19]. A separate study [20] indicated that
the prevalence of C. pneumoniae and M. pneumo-
niae IgG and IgA is high, and that the magnitude
of the antibody levels is highly variable in the
healthy population, which makes the choice of
cut-off levels subjective. Since the cut-off defini-
tion may influence the final conclusion, results
were calculated by both qualitative and quantita-
tive analyses, with the latter being independent of
the precise cut-off level.
It should be noted that this study does not
prove definitively that there is no association
between these two common atypical bacteria and
asthma. Rather, the negative outcome represents a
statistically non-significant phenomenon. Infec-
tions certainly do play a role in asthma, but a
clearer definition of the precise kind of association
is needed. Although the present results did not
show any influence of methodology on the final
conclusion, a deeper understanding of the advan-
tages or shortcomings of particular laboratory
approaches is nonetheless crucial in the context of
clinical decision-making.
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Table 1. Prevalence of seropositivity for Chlomydia
pneumoniae- and Mycoplasma pneumoniae-specific antibodies
Positive (%)a p value
Control
(n = 150)
Asthma
(n =150) Unadjustedb Adjustedc
C. pneumoniae IgA 30.7 37.3 0.272 0.271
C. pneumoniae IgA (LPS) 38.7 46.7 0.199 0.135
C. pneumoniae IgG 52.0 52.0 0.999 0.816
C. pneumoniae IgG (LPS) 59.3 62.0 0.722 0.315
M. pneumoniae IgA 3.3 4.7 0.769 0.351
M. pneumoniae IgG 71.3 70.7 0.999 0.496
aPositive criteria: IgA > 12; IgG > 45; bFisher exact test (two-tail); cAdjusted for
confounding qualitative factors (hypertension, smoking).
Table 2. Comparison of the levels of specific antibodies (expressed in enzyme-immune units) to Chlamydia pneumoniae and
Mycoplasma pneumoniae in asthma patients and healthy controls
Control (n = 150) Asthma (n = 150) p value
Mean ± SD Median Range Mean ± SD Median Range Unadjusteda Adjustedb
C. pneumoniae IgA 12.4 ± 14.9 6.0 0–80 14.4 ± 16.9 9.0 1–86 0.279 0.566
C. pneumoniae IgA (LPS) 14.0 ± 14.6 9.0 0–73 16.5 ± 16.9 11.0 0–86 0.187 0.408
C. pneumoniae IgG 76.4 ± 84.5 47.0 2–443 80.3 ± 93.5 49.0 2–431 0.697 0.877
C. pneumoniae IgG (LPS) 83.0 ± 79.4 57.5 3–391 86.4 ± 83.1 61.5 1–376 0.719 0.902
M. pneumoniae IgA 17.2 ± 13.3 14.0 0–110 18.5 ± 12.9 14.5 4–91 0.412 0.311
M. pneumoniae IgG 124.3 ± 115.3 88.0 9–571 109.0 ± 94.6 79.0 6–432 0.212 0.869
aStudent’s t-test for independent variables; bANOVA model including: group (control, asthma), age, body-mass index, hypertension, smoking.
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